Alterity Therapeutics (PRNAD) Long-Term Deferred Tax (2017 - 2025)

Alterity Therapeutics (PRNAD) has reported Long-Term Deferred Tax for 9 consecutive years, with $31.9 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Long-Term Deferred Tax rose 1.51% year-over-year to $31.9 million; the TTM figure through Jun 2025 stood at $31.9 million (up 1.51% YoY), while the FY2025 annual figure was $31.9 million, up 1.51% from the prior year.
• Long-Term Deferred Tax came in at $31.9 million for Q2 2025 at Alterity Therapeutics, up from $31.5 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $31.9 million in Q2 2025, with the low at $29.4 million in Q2 2023.
• Average Long-Term Deferred Tax over 5 years is $30.8 million, with a median of $31.5 million recorded in 2024.
• Across the five-year window, Long-Term Deferred Tax gained 20.68% in 2021 and slipped 7.03% in 2022, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $31.7 million in 2021, then declined by 7.03% to $29.5 million in 2022, then dropped by 0.23% to $29.4 million in 2023, then increased by 6.89% to $31.5 million in 2024, then increased by 1.51% to $31.9 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $31.9 million, $31.5 million, and $29.4 million for Q2 2025, Q2 2024, and Q2 2023 respectively.